Abstract
ObjectiveAchieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in preclinical...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have